Aurobindo Pharma commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. The company became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, it has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics. Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today, it has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. The formulation business is systematically organized with a divisional structure, and has a focused team for key international markets. The company’s units for APIs / intermediates and units for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.

A well-integrated pharma company, the company features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports many countries across the globe with around 90% of revenues derived from international operations. Its customers include premium multi-national companies. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. It is among the largest filers of DMFs and ANDAs in India.

Business area of the company

Aurobindo Pharma continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.

Aurobindo Pharma Ltd.

Lupin Ltd.

Zydus Lifesciences Ltd.

Alkem Laboratories Ltd.

Abbott India Ltd.

Torrent Pharmaceuticals Ltd.

Gland Pharma Ltd.

Ipca Laboratories Ltd.

Biocon Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Dr. Reddy's Laboratories Ltd.

Ajanta Pharma Ltd.

Cipla Ltd.

JB Chemicals & Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

Open Price	1021.5	Volume	3,136
Prev. Close	1021.55

Performance